Statins in stroke prevention;İnmenin önlenmesinde statinler

Anadolu Kardiyoloji Dergisi

Volumn 8, Issue 3, 2008, Pages 217-222

  Gedikli, Ömer ^a   Baykan, Merih ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Statin; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CHOLESTEROL; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN; SIMVASTATIN;

CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; PRIMARY PREVENTION; RECURRENCE RISK; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; TRANSIENT ISCHEMIC ATTACK; RANDOMIZED CONTROLLED TRIAL;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISCHEMIC ATTACK, TRANSIENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 46049096946     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: Stroke. 2005; 37: 1583-633.
2. American Heart Association. Heart Disease and Stroke Statistics-2004 Update. Dallas, Texas: American Heart Association; 2003.
3. Howard G, Howard VJ, Katholi C, Oli MK, Huston S. Decline in US stroke mortality: an analysis of temporal patterns by sex, race, and geographic region. Stroke. 2001; 32: 2213-20.
4. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989; 320: 904-10.
5. Kagan A, Popper JS, Rhoads GG. Factors related to stroke incidence in Hawaii Japanese men. The Honolulu Heart Study. Stroke 1980; 11: 14-21.
6. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 1990; 301: 309-14.
7. Kearney PM, Baigent C. Statins: Are any questions unanswered? Curr Opin Lipidol 2006;17 418-25.
8. Atkins D, Psaty BM, Koepsell TD, Longstreth WT Jr, Larson EB. Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials. Ann Intern Med 1993; 119: 136-45.
9. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
10. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 336: 1001-9.
11. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
12. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-07.
13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
14. Lee S-H, Bae H-J, Yoon B-W, Kim H, Kim D-E, Roh J-K. Low concentration of serum total cholesterol is associated with multifocal signal loss lesions on gradient-echo magnetic resonance imaging: analysis of risk factors for multifocal signal loss lesions. Stroke 2002; 33: 2845-9.
15. Zhang X, Patel A, Horibe H, Wu Z, Barzi F, Rodgers A, et al. Asia Pacific Cohort Studies Collaboration. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol 2003; 32: 563-72.
16. Bots ML, Elwood PC, Nikitin Y, Salonen JT, FreiredeConcalves A, Inzitari D, et al. Total and HDL cholesterol and risk of stroke. EUROSTROKE: a collaborative study among research centres in Europe. J Epidemiol Community Health 2002; 56 (suppl 1): i19-i24.
17. Horenstein RB, Smith DE, Mosca L, Cholesterol predicts stroke mortality in the Women's Pooling Project. Stroke 2002; 33: 1863-8.
18. Ebrahim S, Sung J, Sono YM, Ferrer RL, Lawlor DA, Davey Smith G. Serum cholesterol, haemorrhagic and ischaemic stroke: the Korean National Health Service prospective cohort study. BMJ 2006; 333: 22.
19. Lindenstrøm, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen city heart study. BMJ 1994; 309:11-5.
20. Wannamethee SG, Shaper AG, Ebrahim S. HDL-cholesterol, total cholesterol, and the risk of stroke in middle-aged British men. Stroke 2000; 31: 1882-8.
21. Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease, and death. The Framingham Study. Arch Intern Med 1981; 141: 1128-31.
22. Koren-Morag N, Tanne D, Graff E, Goldbourt U. Low-and high-density lipoprotein cholesterol and ischemic cerebrovascular disease: the bezafibrate infarction prevention registry. Arch Intern Med 2002; 162: 993-9.
23. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou W, Symeonidis AN, Basayannis EO, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention: the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 2002; 18: 220-8.
24. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-96.
25. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361; 2005-16.
26. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than- average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361: 1149-58.
27. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288: 2998-3007.
28. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PRDSPER): a randomised controlled trial. Lancet 2002; 360: 1623-30.
29. Koren MJ, Hunninghake DB, on behalf of the ALLIANCE investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: The ALLIANCE Study. J Am Coll Cardiol 2004; 44: 1772-9.
30. Pedersen TR, Faergeman O, Kastelein JJP, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin versus usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial. J Am Med Assoc 2006; 294: 2427-45.
31. LaRosa JC, Grundy SM, Waters DD, Shear S, Barter P, Fruchart JC, et al. for the Treating to New Target (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-35.
32. De Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, et al., for the A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. Phase Z of the A to Z trial. J Am Med Assoc 2004; 292: 1307-16.
33. Cannon CP, Braunwald E, McCabe CH, Radar DJ, Rouleau JL, Belder R, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 360: 1495-504.
34. Mazighi M, Lavallee PC, Labreuche J, Amarenco P. Statin therapy and stroke prevention: what was known, what is new and what is next? Curr Opin Lipidol 2007;18: 622-5.
35. Heart Protection Study Collaborative Group. Effect of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363: 757-67.
36. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-59.
37. Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE, Callahan A 3rd, et al, SPARCL Investigators. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2007; 38: 3198-204.
38. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM, et al. for the FASTER Investigators. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007; 6: 961-9.
39. Corvol JC, Bouzamondo A, Sirol M, Hulot S, Sanchez P, Lechat P. Differential effects of lipidlowering therapy on stroke prevention. Arch Intern Med 2003; 163: 669-76.
40. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: a randomized controlled trial. JAMA 2001; 285: 1711-8.
41. Goode T, Miller JP, Heagerty AM. Hyperlipidaemia, hypertension, and coronary heart disease. Lancet 1995; 354: 362-4.
42. Cook NR, Cohen J, Hekbert PR, Taylor JO, Henneckens CH. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995; 155: 701-9.
43. Agabiti-Rosei E, Muiesan ML. Carotid atherosclerosis, arterial stiffness and stroke events. Adv Cardiol. 2007; 44: 173-86.
44. Ichihara A, Hayashi M, Koura Y, Tada Y, Kaneshiro Y, Saruta T. Long-term effects of statins on arterial pressure and stiffness of hypertensives. J Hum Hypertens 2005;19: 103-9.
45. Smilde TJ, van Wissen S, Wollersheim H, Kastelein JJP, Stalenhoef AFH. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia ASAP: a prospective, randomised, double-blind trial. Lancet 2001; 357: 577-81.
46. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002; 106: 2055-60.
47. Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004; 35: 2902-9.
48. Cimino M, Balduini W, Carloni S, Gelosa P, Guerrini U, Tremoli E, et al. Neuroprotective effect of simvastatin in stroke: a comparison between adult and neonatal rat models of cerebral ischemia. Neurotoxicology. 2005; 26: 929-33.
49. Gertz K, Laufs U, Lindauer U, Nickenig G, Bohm M, Dirnagl U, et al. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke 2003; 34: 551-7.
50. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, et al. American Heart Association; American Stroke Association Council on Stroke; Council on Cardiovascular Radiology and Intervention; American Academy of Neurology. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37: 577-617.